Gyre Therapeutics Inc 's Comment on Competition and Industry Peers
ETUARY® is a therapy for idiopathic pulmonary fibrosis (IPF) in the People's Republic of China (PRC), with reported sales of $106.1 million in 2025. Its market share has declined due to increased competition from other approved IPF therapies, including OFEV® (nintedanib), which recorded $76.9 million in PRC sales in 2024.
The biopharmaceutical market for MASH-associated liver fibrosis in the United States is highly competitive. Key factors influencing competition include efficacy, safety, tolerability, reliability, dosing convenience, pricing, generic competition, and reimbursement. Competitors comprise multinational pharmaceutical companies, specialized biotechnology firms, universities, and research institutions. Numerous biotechnology and pharmaceutical companies are developing or marketing treatments targeting the same diseases, with smaller or early-stage companies potentially playing significant roles through collaborations with larger firms. Future competition for Hydronidone in MASH-associated liver fibrosis may emerge from five main drug classes, including Farnesoid X receptor agonists and fibroblast growth factor-related drugs.
July 2, 2024
Gyre Therapeutics Gains NMPA Approval, Marking a Milestone for Treating CLD-Associated Thrombocytopenia in ChinaGyre Therapeutics Announces China s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaGyre Therapeutics, a leading biotechnology company at the forefront of medical innovation, has announced a landmark achievement with the approval of Avatrombopag Maleate Tablets by China’s National Medical Products Administration (NMPA). This approval is a momentous step forward in the therapeutic landscape for patients suffering from chronic liver disease (CLD)-associated thrombocytopenia in China.The approval of Avatrombopag Maleate Tablets underlines the compan...
May 30, 2024
Gyre Pharmaceuticals, a leading global pharmaceutical company, has recently achieved a significant milestone in its quest to combat the debilitating condition of Pulmonary Arterial Hypertension (PAH). The company has received Investigational New Drug (IND) approval from China s National Medical Products Administration (NMPA) to evaluate their groundbreaking drug, F230, in treating PAH. This regulatory approval marks a major step forward in the development and potential availability of an innovative treatment for millions of patients suffering from this life-threatening disease.Gyre Pharmaceuticals Pursuit of a Groundbreaking Treatment:Pulmonary Arterial Hypertension is a rare but severe condition characteri...
March 21, 2024
In a groundbreaking move, Gyre Therapeutics, a pioneering biotech company dedicated to advancing treatments for neurological disorders, has announced the expansion of its esteemed Board of Directors through the appointment of accomplished industry veteran, Rodney L. Nussbaum. This strategic addition marks a significant milestone for the company as it aims to accelerate its mission of revolutionizing the landscape of neurological healthcare.With a proven track record of driving growth and innovation in the pharmaceutical sector, Rodney L. Nussbaum brings a wealth of expertise and a razor-sharp focus on advancing therapeutics for patients suffering from debilitating neurological disorders. His extensive experi...
Sources:
Gyre Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gyre Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
